Hi Josh, I don't have any selling levels on #AVCT for my core holding, as I think the upside is, for all intents and purposes, unlimited now from a $460m mkt cap. AVA6103 could be a $40, $50, $60 billion per annum drug - and that's just if the pre-clinical data is matched in the clinic. There is almost every reason to think that it will in fact be surpassed, as was pointed out by @avacta during the recent Science Day. Big Pharma is paying what, 3-6x peak sales for acquirees' lead candidate? And in my view, 6103 is considerably more derisked than most seem to think. To revert to your question: my target is to hold until an offer is accepted by >75% of shareholders, and I'm forced to sell! But given how many retail holders - which makes up >95% of the register - is invested fully (not just capital-wise but sentimentally too), I think the final price that the likes of AstraZeneca, Novartis, Merck etc. will have to pay will be incredibly high. P.S. selloff today is almost certainly due to a dozen or so traders exiting in order to chase MKA and IES. All very predictable. Alas, nothing to be done (except of course take advantage of the dip, if one has spare capital! N.B. not investment advice blah blah blah! 😂).
